Top-Rated StocksTop-RatedNASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis $7.28 -0.11 (-1.49%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$7.17▼$7.4650-Day Range$7.28▼$13.9852-Week Range$3.21▼$18.33Volume8.61 million shsAverage Volume7.90 million shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/APrice Target$24.45 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Iovance Biotherapeutics alerts: Email Address Iovance Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside235.9% Upside$24.45 Price TargetShort InterestBearish24.42% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.76Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.34) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.64 out of 5 starsMedical Sector223rd out of 879 stocksBiological Products, Except Diagnostic Industry28th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIovance Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Iovance Biotherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted24.42% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 9.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 3.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 42.33% net impact score from Upright. Iovance Biotherapeutics seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.82. Previous Next 2.1 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.Search InterestOnly 44 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat FollowsOnly 29 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.34) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Iovance Biotherapeutics Stock (NASDAQ:IOVA)Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More IOVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOVA Stock News HeadlinesJuly 5 at 7:56 AM | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 0.1%July 4, 2024 | americanbankingnews.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Growth in Short InterestJuly 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… July 3, 2024 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Trading 1.7% Higher June 30, 2024 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 1.6%June 30, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Iovance Biotherapeutics (NASDAQ:IOVA)June 28, 2024 | globenewswire.comIovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced MelanomaJune 28, 2024 | fool.comIs It Too Late to Buy Iovance Biotherapeutics Stock?July 8, 2024 | Crypto 101 Media (Ad)[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… June 26, 2024 | seekingalpha.comIovance Biotherapeutics: Amtagvi Launch Continues UpwardJune 21, 2024 | globenewswire.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)June 21, 2024 | investorplace.com3 Top Penny Stocks to Skyrocket Your Wealth in 2024May 29, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)May 29, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)May 24, 2024 | msn.comWhat's Going On With Iovance Biotherapeutics Today?May 24, 2024 | globenewswire.comIovance Biotherapeutics to Present at Upcoming Conferences and EventsMay 23, 2024 | globenewswire.comIovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual MeetingMay 22, 2024 | fool.comBull Market Buys: 2 Growth Stocks to Own for the Long RunSee More Headlines Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/08/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees557Year Founded2013Price Target and Rating Average Stock Price Target$24.45 High Stock Price Target$34.00 Low Stock Price Target$17.00 Potential Upside/Downside+235.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-444,040,000.00 Net Margins-23,615.70% Pretax Margin-23,872.37% Return on Equity-71.45% Return on Assets-55.17% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.42 Sales & Book Value Annual Sales$1.19 million Price / Sales1,711.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book3.19Miscellaneous Outstanding Shares279,830,000Free Float250,730,000Market Cap$2.04 billion OptionableOptionable Beta0.63 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Frederick G. Vogt Esq. (Age 50)J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary Comp: $1.39MMr. Jean-Marc Bellemin M.B.A. (Age 51)CFO, Principal Accounting Officer & Treasurer Comp: $932.2kDr. Igor P. Bilinsky (Age 51)Chief Operating Officer Comp: $932.2kDr. Friedrich Graf Finckenstein M.D. (Age 57)Chief Medical Officer Comp: $1.06MMs. Sara PellegrinoVice President of Investor Relations & Public RelationsMs. Tracy WintonSenior Vice President of Human ResourcesMr. Howard B. Johnson M.B.A. (Age 64)Chief Business Officer Mr. James Ziegler M.B.A.Executive Vice President of CommercialDr. Raj K. Puri M.D.Ph.D., Executive VP of Regulatory Strategy & Translational MedicineMr. Brian Shew M.B.A.Senior VP & Head of Digital and Information TechnologyMore ExecutivesKey CompetitorsFate TherapeuticsNASDAQ:FATENektar TherapeuticsNASDAQ:NKTRChina Biologic ProductsNASDAQ:CBPORepligenNASDAQ:RGENExelixisNASDAQ:EXELView All CompetitorsInsiders & InstitutionsDNB Asset Management ASBought 11,091 shares on 7/5/2024Ownership: 0.010%Transcend Capital Advisors LLCBought 22,500 shares on 7/2/2024Ownership: 0.008%Farallon Capital Management LLCSold 536,000 shares on 5/24/2024Ownership: 0.009%Zimmer Partners LPSold 451,500 shares on 5/17/2024Ownership: 0.016%Walleye Trading LLCBought 25,500 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions IOVA Stock Analysis - Frequently Asked Questions How have IOVA shares performed this year? Iovance Biotherapeutics' stock was trading at $8.13 at the beginning of 2024. Since then, IOVA shares have decreased by 10.5% and is now trading at $7.28. View the best growth stocks for 2024 here. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its earnings results on Thursday, May, 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.03. The firm's revenue for the quarter was up 71400.0% on a year-over-year basis. Who are Iovance Biotherapeutics' major shareholders? Top institutional investors of Iovance Biotherapeutics include DNB Asset Management AS (0.01%) and Transcend Capital Advisors LLC (0.01%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Iain D Dukes and Frederick G Vogt. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN) and Xtrackers California Municipal Bond ETF (CA). This page (NASDAQ:IOVA) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IOVA Stock Alerts